-- Days : -- HRS : -- MIN : -- SEC
Register Now →

All News

Bristol Myers Squibb announced the commercial launch of Zeposia (ozanimod) for relapsing multiple sclerosis (RMS). The oral treatment is the first and only approved sphingosine-1-phosphate receptor modulator with no genetic test or first dose observation at initiation.

Research has established an association between social risk factors and child health outcomes, while professional medical organizations have endorsed screening for such factors in clinical settings. Providing an in-person patient navigator to address family social needs leads to a decrease in child health care utilization, according to a study published in JAMA Network Open.

A comprehensive workplace wellness program was shown to increase the proportion of employees with a designated primary care physician and improve employee beliefs on their own health. However, no significant effects were observed on physical health outcomes, rates of medical diagnoses, or health care service use, according to study findings published this week.